加州太平洋生物科學公司 PACB 深 滬
已收盤 09-05 16:00:00 美东时间
1.27
+0.030
+2.42%
華盛通- 最 高1.28
- 今 開1.26
- 成交量 378.91万股
- 最 低 1.22
- 昨 收 1.24
- 總市值 3.81亿
- 52周最高 2.72
- 市盈率 靜 --
- 換手率 1.26%
- 52周最低 0.8511
- 委 比 -0.68%
- 總股本 3.00亿
- 歷史最高 53.69
- 量 比 1.03
- 振 幅 4.84%
- 歷史最低 0.8511
- 每 手 1
- 風險率 2.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多EpiCypher Joins PacBio Compatible Program To Enhance Single-Molecule Chromatin Sequencing With CUTANA Hia5 Enzyme
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that EpiCypher, a recognized leader in epigenetics tools, has joined the PacBio Compatible program. The
09-03 21:06
PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow
PacBio and EpiCypher have partnered to integrate EpiCypher’s CUTANA® Hia5 enzyme with PacBio’s Fiber-seq assays, enabling single-molecule chromatin fiber sequencing. This collaboration allows researchers to simultaneously measure chromatin accessibility, DNA methylation, and genetic variation, advancing rare disease and cancer research. The integrated workflow provides insights into gene regulation and genomic complexities, consolidating multiple...
09-03 13:05
The Analyst Verdict: Pacific Biosciences In The Eyes Of 4 Experts
Pacific Biosciences (NASDAQ:PACB) underwent analysis by 4 analysts in the last ...
08-12 02:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
PacBio And Partners Publish Benchmark Study In 'Nature Methods', Enhancing Genomic Accuracy And Reducing AI Variant Errors By 34%
PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of a study published in Nature Methods describing a new, comprehensive truth-set of genomic
08-04 21:24
Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models
PacBio and collaborators have developed the Platinum Pedigree dataset, a comprehensive genomic variation benchmark built using long-read sequencing and inheritance-based validation. This resource improves AI-driven variant classification, such as Google’s DeepVariant, achieving a 34% reduction in errors. The dataset includes difficult-to-sequence regions and is publicly available to advance genomics research and clinical applications.
08-04 13:05
PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications
PacBio announced the first Arab human pangenome study published in *Nature Communications*, revealing millions of previously unknown variants and 111 million base pairs of unsequenced DNA. The study, led by MBRU, assembled high-resolution genomes from 53 individuals across eight countries. This advancement improves genomic equity for underrepresented Arab populations, enhancing disease risk understanding and precision medicine. The research, powe...
07-24 13:05
PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio
PacBio joins the 1000 Genomes Long Read Sequencing Project, contributing Iso-Seq data from ~1,000 samples using its Kinnex RNA kits and Revio platform. This collaboration aims to enhance transcriptome insights, improve gene expression analysis, and provide a shared resource for the genetics community. Data and tools will be openly available, supporting diverse applications from basic biology to diagnostics.
07-23 13:05
PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025
PacBio announced its quarterly conference call to discuss Q2 2025 financial results on August 7, 2025, at 5:00 pm ET (2:00 pm PT). The call will be webcast via PacBio’s website or accessible via toll-free and international phone numbers. PacBio is a leading life science technology company providing advanced sequencing solutions for various research applications. For more information, contact investors at ir@pacb.com or media at pr@pacb.com.
07-21 20:05
美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
